We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dynamic PET acquisition-a Quantitative Technique for Grading of Malignant Tumors and Prediction of Response to Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00294840
Recruitment Status : Completed
First Posted : February 22, 2006
Last Update Posted : July 29, 2010
Sponsor:
Information provided by:
Rambam Health Care Campus

Brief Summary:
To assess a quantitative kinetic model of FDG uptake measurement using PET in patients with aggressive Non-Hodgkin's lymphoma and cancer of the pancreas, malignancies with known variability in disease aggressiveness and prognosis, for optimized tailoring of the therapeutic strategy in the individual patient.

Condition or disease Intervention/treatment Phase
Pancreatic Cancer Device: PET-CT Early Phase 1

Study Type : Observational
Estimated Enrollment : 70 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Dynamic FDG-PET in Aggressive Lymphoma and Pancreas Cancer
Study Start Date : August 2006
Primary Completion Date : September 2009
Study Completion Date : April 2010

Resource links provided by the National Library of Medicine

U.S. FDA Resources




Primary Outcome Measures :
  1. The impact of the imaging modality on patient management [ Time Frame: 5 years ]

Secondary Outcome Measures :
  1. patient management [ Time Frame: 10 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with pancreatric cancer
Criteria

Inclusion Criteria:

  • age>18
  • newly diagnosed untreated aggressive NHL
  • newly diagnosed untreated cancer of pancreas

Exclusion Criteria:


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00294840


Locations
Israel
Rambam Medical Center
Haifa, Israel
Sponsors and Collaborators
Rambam Health Care Campus
Investigators
Principal Investigator: Ora Israel, MD Rambam Health Care Campus

Responsible Party: Dr. Alex Frenkel, Rambam HealthCare Campus
ClinicalTrials.gov Identifier: NCT00294840     History of Changes
Other Study ID Numbers: PETDCTIL
First Posted: February 22, 2006    Key Record Dates
Last Update Posted: July 29, 2010
Last Verified: May 2008

Additional relevant MeSH terms:
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases